Holen Sie sich die Stockscreener-App
4.36
7.39%
0.30
Handel nachbörslich:
29.72
25.36
+581.65%
Schlusskurs vom Vortag:
$4.06
Offen:
$4.12
24-Stunden-Volumen:
611.14K
Relative Volume:
0.59
Marktkapitalisierung:
$319.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.79M
KGV:
-1.3333
EPS:
-3.27
Netto-Cashflow:
$-51.66M
1W Leistung:
+4.56%
1M Leistung:
+10.38%
6M Leistung:
+522.68%
1J Leistung:
+1,088%
1-Tages-Spanne:
$4.01
$4.45
1-Wochen-Bereich:
$3.995
$4.72
52-Wochen-Spanne:
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Firmenname
Relmada Therapeutics Inc
Sektor
Branche
Telefon
646 876 3459
Adresse
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Vergleichen Sie RLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.49 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.17 | 303.77M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
5.04 | 221.34M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.67 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.76 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-05 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-09-17 | Hochstufung | Jefferies | Hold → Buy |
| 2024-06-05 | Herabstufung | Goldman | Neutral → Sell |
| 2022-10-14 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-10-14 | Herabstufung | Truist | Buy → Hold |
| 2022-10-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Eingeleitet | Mizuho | Buy |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-10-28 | Herabstufung | Goldman | Buy → Neutral |
| 2020-07-14 | Eingeleitet | Oppenheimer | Outperform |
| 2020-05-04 | Eingeleitet | SunTrust | Buy |
| 2020-04-21 | Eingeleitet | Goldman | Buy |
| 2020-01-27 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Relmada Therapeutics Amends Executive Employment Agreements - TipRanks
Relmada Therapeutics updates executive contracts and increases salaries - Investing.com
What analysts say about Relmada Therapeutics Inc stockMarket Insider Reports & Exceptional Profit Growth Tips - earlytimes.in
Aug Drivers: Can Relmada Therapeutics Inc stock outperform in 2025 bull marketAnalyst Upgrade & Safe Entry Trade Reports - moha.gov.vn
Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Taking on analysts’ expectations and winning: Relmada Therapeutics Inc (RLMD) - setenews.com
Relmada Therapeutics (RLMD) Price Target Increased by 900.00% to 10.20 - Nasdaq
Can Relmada Therapeutics Inc. stock hit analyst price targetsM&A Rumor & Technical Pattern Based Signals - Newser
Will Relmada Therapeutics Inc. (4E2) stock outperform value peersJuly 2025 Chart Watch & Fast Entry High Yield Stock Tips - Newser
Will Relmada Therapeutics Inc. stock deliver strong dividend growthGap Down & Risk Adjusted Buy and Sell Alerts - Newser
Relmada Therapeutics’ Earnings Call Highlights Clinical and Financial Success - MSN
Relmada’s bladder cancer therapy shows 92% complete response rate By Investing.com - Investing.com Nigeria
Relmada’s bladder cancer therapy shows 92% complete response rate - Investing.com India
Relmada Therapeutics Advances NDV-01 for Non-Muscle Invasive Bladder Cancer with Positive Phase 2 Follow-Up Data - Quiver Quantitative
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewswire
A History of Outperforming Analyst Forecasts and Beating the Odds: Relmada Therapeutics Inc (RLMD) - setenews.com
Why Relmada Therapeutics Inc. (4E2) stock stays resilientRecession Risk & Trade Opportunity Analysis - Newser
Relmada Therapeutics (RLMD) Stock Analysis Report | Financials & Insights - Benzinga
What risks investors should watch in Relmada Therapeutics Inc. stockTrade Ideas & Fast Moving Trade Plans - Newser
How supply chain issues affect Relmada Therapeutics Inc. stockQuarterly Earnings Report & Long-Term Growth Plans - moha.gov.vn
Relmada Therapeutics Inc. (US75955J4022.SG) Balance Sheet - Yahoo! Finance Canada
Relmada Therapeutics Announces $100 Million Underwritten Offering - globallegalchronicle.com
Relmada Therapeutics Inc 4E2 Stock Analysis and ForecastVolume Analysis Techniques & Rapid Portfolio Trading - earlytimes.in
Pullback Watch: Is Relmada Therapeutics Inc. stock supported by innovation pipelineWeekly Trading Summary & Fast Momentum Entry Tips - moha.gov.vn
Is Relmada Therapeutics Inc. stock supported by strong cash flows - BỘ NỘI VỤ
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - Markets Financial Content
Views of Wall Street’s Leading Experts on Relmada Therapeutics Inc - Setenews
Relmada Therapeutics Inc. (RLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Relmada cut to neutral by Mizuho on Phase 3 study failure - MSN
Relmada Therapeutics, Inc. (RLMD) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
How risky is Relmada Therapeutics Inc. stock now2025 Key Lessons & Growth Focused Entry Reports - newser.com
How Relmada Therapeutics Inc. (4E2) stock trades in high volatilityEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
This Stock Is Up 704% in 2025 But Has No Products to Its Name - inkl
Will Relmada Therapeutics Inc. stock sustain high P E ratiosCEO Change & Consistent Growth Equity Picks - newser.com
Is Relmada Therapeutics Inc. showing signs of accumulationQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - newser.com
Mizuho upgrades Relmada Therapeutics stock to Outperform on NDV-01 potential - Investing.com Nigeria
Smart tools for monitoring Relmada Therapeutics Inc.’s price actionWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - newser.com
Mizuho Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Will Relmada Therapeutics Inc. (4E2) stock outperform small cap peers - newser.com
What valuation ratios show for Relmada Therapeutics Inc. (4E2) stock - newser.com
Mizuho Upgrades RLMD to 'Outperform', Raises Price Target | RLMD Stock News - GuruFocus
Relmada Therapeutics (RLMD) Receives Upgrade with Significant Up - GuruFocus
Relmada Therapeutics upgraded by Mizuho with a new price target - Quantisnow
Finanzdaten der Relmada Therapeutics Inc-Aktie (RLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):